Related Experiment Video
Updated: May 3, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
[Enzyme replacement therapy for hypophosphatasia]
1Department of Pediatrics, Osaka University Graduate School of Medicine, Japan.
Insights
Enzyme replacement therapy using bone-targeting recombinant alkaline phosphatase (ALP) shows promise for treating hypophosphatasia, a condition causing impaired bone calcification. Clinical trials indicate efficacy and safety, with expanded trials ongoing.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Context:
- Hypophosphatasia (HPP) is a rare genetic disorder.
- It results from mutations in the gene encoding tissue-nonspecific alkaline phosphatase (ALP).
- This leads to impaired bone mineralization and severe health complications, particularly in infants.
Purpose:
- To evaluate the efficacy and safety of enzyme replacement therapy (ERT) for hypophosphatasia.
- To investigate the use of a bone-targeting recombinant ALP in treating HPP.
- To assess the therapeutic potential of ERT in preclinical models and clinical trials.
Summary:
- Abnormal tissue-nonspecific alkaline phosphatase (ALP) causes hypophosphatasia, leading to impaired bone calcification and high infant mortality.
- A novel bone-targeting recombinant ALP has been developed for enzyme replacement therapy (ERT).
- ERT demonstrated efficacy in hypophosphatasia model mice and has shown positive results in clinical trials for perinatal and infantile HPP.
Impact:
- ERT offers a potential therapeutic strategy for hypophosphatasia, addressing a critical unmet medical need.
- Successful clinical trials could lead to an approved treatment for severe forms of HPP.
- Ongoing expanded trials aim to further establish the long-term safety and efficacy of this innovative therapy.
Abstract:
Hypophosphatasia is caused by abnormal tissue-nonspecific alkaline phosphatase (ALP), leading to impaired calcification in bone. Patients with severe hypophosphatasia have difficulties in respiratory function from early days after birth and the rate of lethality is extremely high. Enzyme replacement therapy using bone-targeting recombinant ALP, which has 10 aspartic acids in the C-terminal tail has developed. The efficacy of ERT was firstly observed in model mice of hypophosphatasia. In clinical trial including perinatal and infantile types of hypophosphatasia, efficacy and safety have been reported. Expanded clinical trial is underway and the results of the clinical trial might be reported by the end of the next year.
Related Concept Videos
Phosphorylation
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Chronic Kidney Disease III: Interprofessional Care
Enzyme Inhibition
Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily...

